Could GLP-1 receptor agonists like semaglutide treat addiction, Alzheimer disease, and other conditions
Pharmacovigilance studies indicate that GLP-1RAs, with the exception of albiglutide, demonstrate potential associations with pancreatic cancer risk, particularly evident in exenatide-treated patients who exhibit elevated cancer incidence rates
Our experience confirms this: Melanotan-2 users consistently report visible tanning after 710 days at 0.51.0 mg daily dosing, while PT-141 users show no pigmentation changes even after 46 weeks
Storage Store out of reach of small children, at room temperature, in a closed container and in a dry place
That glucose-dependent action is why GLP-1s rarely cause hypoglycemia unless combined with insulin or sulfonylureas
doi: 10.1016/j.bbrc.2023.149131 460 YangSShangJLiuLTangZMengX